ORAMED PHARMACEUTICALS INC. Deferred Revenue, Revenue Recognized
ORAMED PHARMACEUTICALS INC. (ORMP) reported Deferred Revenue, Revenue Recognized of $20.38 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-06.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2024-03-06
- ORAMED PHARMACEUTICALS INC. deferred revenue, revenue recognized for the quarter ending 2023-03-31 was $19.71M, a 15.90% increase year-over-year.
- ORAMED PHARMACEUTICALS INC. deferred revenue, revenue recognized for the quarter ending 2022-03-31 was $17.00M.
- ORAMED PHARMACEUTICALS INC. deferred revenue, revenue recognized for the quarter ending 2021-11-30 was $16.11M.
- ORAMED PHARMACEUTICALS INC. deferred revenue, revenue recognized for the quarter ending 2017-11-30 was $611.00K.
- ORAMED PHARMACEUTICALS INC. deferred revenue, revenue recognized for fiscal 2023 was $20.38M, a 7.04% increase from fiscal 2022.
- ORAMED PHARMACEUTICALS INC. deferred revenue, revenue recognized for fiscal 2022 was $19.04M.
- ORAMED PHARMACEUTICALS INC. deferred revenue, revenue recognized for fiscal 2021 was $15.44M.
- ORAMED PHARMACEUTICALS INC. deferred revenue, revenue recognized for fiscal 2019 was $2.70M, a 10.37% increase from fiscal 2018.
| Period end | Deferred Revenue, Revenue Recognized 3 month | Deferred Revenue, Revenue Recognized 4 month | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 9 month | Deferred Revenue, Revenue Recognized 12 month | Deferred Revenue, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-12-31 | $20.38M 10-K · filed 2024-03-06 | |||||
| 2023-09-30 | $20.38M 10-Q · filed 2023-11-09 | |||||
| 2023-06-30 | $20.38M 10-Q · filed 2023-08-10 | |||||
| 2023-03-31 | $19.71M 10-Q · filed 2023-05-11 | |||||
| 2022-12-31 | $19.04M 10-K · filed 2023-03-06 | |||||
| 2022-09-30 | $18.36M 10-Q · filed 2022-11-10 | |||||
| 2022-06-30 | $17.68M 10-Q · filed 2022-08-10 | |||||
| 2022-03-31 | $17.00M 10-Q · filed 2022-05-12 | |||||
| 2021-12-31 | $16.34M 10-QT · filed 2022-03-30 | |||||
| 2021-11-30 | $16.11M 10-Q · filed 2022-01-11 | |||||
| 2021-08-31 | $15.44M 10-K · filed 2021-11-24 | |||||
| 2019-08-31 | $2.70M 10-K · filed 2019-11-27 | |||||
| 2018-08-31 | $2.45M 10-K · filed 2019-11-27 | |||||
| 2018-05-31 | $1.83M 10-Q · filed 2018-07-12 | |||||
| 2018-02-28 | $1.22M 10-Q · filed 2018-04-09 | |||||
| 2017-11-30 | $611.00K 10-Q · filed 2018-01-11 | |||||
| 2017-08-31 | $2.46M 10-K · filed 2018-11-28 | |||||
| 2016-08-31 | $641.00K 10-K · filed 2017-11-29 | $2.16M 10-K · filed 2016-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |